Zobrazeno 1 - 6
of 6
pro vyhledávání: '"M. Yu. Pomazanova"'
Publikováno v:
Medical alphabet. :71-74
The article presents the results of clinical studies and real practice of the effectiveness and safety of the use of a new genetically engineered biological drug Risankizumab. Skyrizi (risankizumab) is an innovative drug, it is a humanized monoclonal
Publikováno v:
Medical alphabet. :35-38
Psoriasis is one of the most common chronic immune-mediated skin diseases. One of the widely discussed gastroenterological comorbidities of psoriasis is chronic inflammatory diseases of the gastrointestinal tract. The article presents the results of
Publikováno v:
Medical alphabet. :79-82
Publikováno v:
Medical alphabet. :48-52
The escape effect or secondary ineffectiveness of genetically engineered bio-drugs GEBD determines the change in patient management tactics, including switching to another genetically engineered drug. In clinical practice, this is a rather difficult
Publikováno v:
Medical alphabet. :28-33
Psoriasis refers to genetically deterministic chronic inflammatory dermatoses, which are characterized by systemic immuno-mediated inflammatory response with preferential activation of the IL -23/-17 axis, growth deviation and keratinocyte differenti
Publikováno v:
Medical alphabet. :21-23
Psoriasis is one of the most common chronic recurrent dermatoses, which is not limited to skin lesions, leading to a violation of the functions of various body organ systems. The article presents the results of the analysis of the medical histories o